abstract |
There is provided a composition comprising IL-21 polypeptide and a composition comprising a tyrosine kinase inhibitor, for use in treating cancer selected from renal cell carcinoma, metastatic melanoma, or hepatocellular carcinoma, wherein said use comprises co-administration of said compositions to a patient. |